Compound name
GSK0660
Protein family
Nuclear Receptors
Target name
NR1C1
Affinity on-target cellular (nM)
6107
CG-Set
Nuclear Receptor set
Recommended Concentration
10 µM
Compound EUbOPEN ID
EUB0001150a
SMILES
O=S(NC(C=C1)=C(OC)C=C1NC2=CC=CC=C2)(C3=C(C(OC)=O)SC=C3)=O
InChIKey
NDFKBGWLUHKMFY-UHFFFAOYSA-N
Mode of action
Antagonist
Affinity on-target cellular definition
IC50
Affinity on-target cellular assay type
Gal4 hybrid reporter gene assay (HEK293T cells were cotransfected with pFR-Luc reporter, pRL-SV40 control reporter and pFA-CMV-hPPAR? or -hPPAR?- or hPPAR?-LBD expression plasmid; GW7647 1 µM (PPAR?), L-165,041 1 µM (PPAR?) and rosiglitazone 1 µM (PPAR?) are used for receptor activation)
Affinity on-target cellular relation
0
Selectivity platform
Nuclear receptor panel, bromodomain and kinase panel
Selectivity platform number of targets
20
Selectivity remarks
Screened at 10 µM against NR2A1, NR2B1, NR2C1, NR2E1, NR4A1, NR5A1 and VP16 in a Gal4 hybrid reporter gene assay (HEK293T cells were cotransfected with pFR-Luc reporter, pRL-SV40 control reporter and pFA-CMV containing the Gal4-DBD fused with human NR-LBD of interest or pECE-SV40-Gal4-VP16): clean selectivty profile with no significant agonism/antagonism detected; Screened at 20 µM in a bromodomain and kinase panel against ABL1, AURKA, BRD4, BRPF1, CDK2, CSNK1D, FGFR3, GSK3B, MAPK1, TRIM24 in DSF assays: clean selectivity profile with no significant binding (?Tm < 2 K)